Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

计划入组 236 人 · 首次发布于 2019 年 3 月 7 日

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster

计划入组 600 人 · 首次发布于 2022 年 7 月 20 日

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

计划入组 410 人 · 首次发布于 2022 年 7 月 19 日

Recombinant viral vector

SARS-CoV-2 CoVacHGMix Type 5 Adenoviral Vector Vaccine

rVSV vector vaccine (Emergent BioSolutions/Coalition for Epidemic Preparedness Innovations)

Frantz Viral Therapeutics, LLC

United States

VIETNAM VIRAL HEPATITIS ALLIANCE

United States

Advanced Viral Research Corp

The Bahamas

Global Study Links COVID-19 Vaccines to Rare Adverse Events

Global Vaccine Sales Market to Reach US$141.40 Billion by 2036 as Next-Generation Platforms Accelerate Growth

Vaccine Adjuvants Market Projected to Reach USD 6.19 Billion by 2035, Driven by mRNA and Oncology Vaccine Innovation